Ticagrelor Market Outlook Through 2030: Understanding The Growth Opportunity
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Ticagrelor Market CAGR Outlook And Future Development
The ticagrelor market size has shown substantial growth in recent years. It is projected to expand from $1.93 billion in 2025 to $2.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The expansion observed in the historical period stems from various factors, including the restricted availability of antiplatelet therapies, an increasing prevalence of cardiovascular disease, the broadening of hospital pharmacy networks, a rise in clinical trials for cardiovascular drugs, and enhanced awareness regarding heart attack and stroke risks.
The ticagrelor market is projected to experience robust expansion over the coming years, with its valuation anticipated to reach $2.75 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. This growth during the forecast period is attributable to several factors, including the introduction of extended-release ticagrelor tablets, the broadening of retail and online pharmacy distribution channels, the growing embrace of personalized cardiovascular treatment, escalating government efforts for cardiovascular disease prevention, and the incorporation of digital health monitoring systems. Key trends shaping the forecast period encompass the increasing application of ticagrelor in managing acute coronary syndrome, a rising inclination towards oral antiplatelet therapy instead of injectable alternatives, the expansion of hospital-based and ambulatory cardiology services, heightened awareness regarding stroke and myocardial infarction prevention, and the continued development of extended-release ticagrelor formulations.
Get A Free Sample Report With In-Depth Market Insights:
Ticagrelor Market Growth Momentum: What Factors Are Shaping Demand?
The escalating incidence of cardiovascular diseases is anticipated to drive the expansion of the ticagrelor market moving forward. These conditions refer to a range of disorders impacting the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. The increasing occurrence of cardiovascular diseases is mainly linked to unhealthy dietary choices, as consuming excessive amounts of saturated fats, trans fats, added sugars, and sodium contributes to high blood pressure, obesity, and elevated cholesterol, all major risk factors for heart-related ailments. Ticagrelor assists in treating cardiovascular diseases by preventing platelet aggregation, thereby lowering the risk of blood clots. This mechanism enhances patient outcomes by reducing the chances of heart attacks and strokes, especially in high-risk individuals. For instance, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023, as reported in January 2024. Therefore, the rising prevalence of cardiovascular diseases is propelling the growth of the ticagrelor market.
Ticagrelor Market Segment Landscape: Which Areas Lead Development?
The ticagrelor market covered in this report is segmented –
1) By Type: 90 mg Tablet, 60 mg Tablet
2) By Drug Class: Antiplatelet Agents, Antithrombotic Agents
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Acute Coronary Syndrome, Myocardial Infarction, Stroke Prevention, Other Applications
5) By End User: Hospitals And Clinics, Ambulatory Centers, Other End Users
Ticagrelor Market Trends Redefining Industry Growth
Leading firms in the ticagrelor market are actively seeking regulatory approvals to broaden product applications, enhance market access, and strengthen their competitive position. Such regulatory approvals denote the official permission granted by governmental bodies for the marketing and sale of a product, ensuring adherence to safety, efficacy, and quality standards. For instance, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, secured an abbreviated new drug application (ANDA) from the US Food & Drug Administration (USFDA) for its generic ticagrelor tablets 90 mg and received tentative approval for the 60 mg strength. These tablets are prescribed to lower the risk of cardiovascular events and operate by inhibiting platelet aggregation, thereby preventing the formation of blood clots.
Ticagrelor Market Industry Leaders And Competitive Landscape
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.
View The Full Ticagrelor Market Report:
Ticagrelor Market Geographic Distribution And Regional Opportunities
North America was the largest region in the ticagrelor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
